Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jan;2(1):3-6.
doi: 10.1158/1940-6207.CAPR-08-0218.

Retinoid chemoprevention trials: cyclin D1 in the crosshairs

Sarah J Freemantle  1 , Yongli Guo, Ethan Dmitrovsky
Affiliations
Review

Retinoid chemoprevention trials: cyclin D1 in the crosshairs

Sarah J Freemantle et al. Cancer Prev Res (Phila). 2009 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

E. Dmitrovsky serves on the scientific advisory board of NuRx but has no ownership or financial interests in NuRx.

Figures

Fig. 1
Fig. 1
The different domains and structures of transcripts and protein products for cyclin D1 (A) and cyclin D1b (B). Translation from cyclin D1b mRNA terminates in intron 4 (14). The exonic (E) structure and location of key cyclin D1 regulatory domains (such as the retinoblastoma binding motif, pRB, cyclin box, and PEST site) for cyclin D1 and cyclin D1b are shown. Arrows depict important residues involved in the regulation of these cyclin D1 species, as discussed in the text.
See this image and copyright information in PMC

Comment on

  • Cyclin D1 and cancer development in laryngeal premalignancy patients.
    Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN Jr, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK. Papadimitrakopoulou V, et al. Cancer Prev Res (Phila). 2009 Jan;2(1):14-21. doi: 10.1158/1940-6207.CAPR-08-0111. Cancer Prev Res (Phila). 2009. PMID: 19139013 Free PMC article. Clinical Trial.
  • High-dose fenretinide in oral leukoplakia.
    William WN Jr, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. William WN Jr, et al. Cancer Prev Res (Phila). 2009 Jan;2(1):22-6. doi: 10.1158/1940-6207.CAPR-08-0100. Cancer Prev Res (Phila). 2009. PMID: 19139014 Free PMC article. Clinical Trial.

References

    1. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids) Fed Proc. 1976;35:1332–1338. - PubMed
    1. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315:1501–1505. - PubMed
    1. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990;323:795–801. - PubMed
    1. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol. 1993;11:1216–1222. - PubMed
    1. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of tretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001;93:605–618. - PubMed